Full Press Release Details
CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies.
CRSP
CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies
Key Takeaway: CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.4%
average across 2 past catalysts
Cash runway
~84 mo
Minimal dilution risk
Lead asset
CTX340
Phase 1 · Hypertension